Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC

The aim of this clinical trial is to find out whether Regorafenib and Sintilimab in combination with electroacupuncture works in treating participants with microsatellite stable (MSS) advanced colorectal cancer who have failed one or more second-line standard chemotherapy regimens. It will also learn about the efficacy and safety of the combination therapy. The main questions the trial aims to answer are: Does combination therapy reduce the overall survival time ? What medical problems do people have when they take combination therapy? Participants will Regorafenib, take for 2 weeks and sto

Trial Details

NCT ID
NCT06456515
Phase
NA
Sponsor
The First People's Hospital of Changzhou
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Regorafenib and Sintilimab in combination with electroacupuncture
Locations (sample)
  • Changzhou, China|31.77359,119.95401

Key Eligibility Criteria

  • Fullly knowledge of the study and voluntarily sign the informed consent;
  • Histologically and/or cytologically confirmed metastatic colorectal adenocarcinoma (Stage IV) with microsatellite stable (MSS)\* confirmed by PCR o…
  • Receive at least two lines of standard chemotherapy in the past and have failed.
  • No systemic chemotherapy or antitumor therapy such as radiotherapy, immunotherapy, biological or hormonal therapy in the past 4 weeks; and have nev…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →